Regulus Therapeutics
RGLS
£6.11
Share price
0.00%
Change (1 day)
328.62%
Change (1 year)
Categories
Regulus Therapeutics (RGLS) - Cash on Hand
Cash on Hand as of March 2025 : £48.94 Million
According to Regulus Therapeutics's latest financial reports the company has £48.94 Million in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Regulus Therapeutics - Cash on Hand chart (from 2011 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | £60.38 M | 223.68% |
| 2023-12-31 | £18.65 M | -42.37% |
| 2022-12-31 | £32.36 M | -27.64% |
| 2021-12-31 | £44.73 M | 96.14% |
| 2020-12-31 | £22.8 M | -12.35% |
| 2019-12-31 | £26.02 M | 137.03% |
| 2018-12-31 | £10.97 M | -75.3% |
| 2017-12-31 | £44.44 M | -27.94% |
| 2016-12-31 | £61.68 M | -19.86% |
| 2015-12-31 | £76.96 M | -24.98% |
| 2014-12-31 | £0.10 B | 48.45% |
| 2013-12-31 | £69.11 M | 13.87% |
| 2012-12-31 | £60.69 M | 147.32% |
| 2011-12-31 | £24.54 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 GlaxoSmithKline GSK | £4.33 B | 8,765.22% | 🇬🇧 UK |
 Sanofi SNY | £6.47 B | 13,125.69% | 🇫🇷 France |
 Biogen BIIB | £1.94 B | 3,874.88% | 🇺🇸 USA |
 AstraZeneca AZN | £4.03 B | 8,153.27% | 🇬🇧 UK |
 Alnylam Pharmaceuticals
ALNY | £1.97 B | 3,926.77% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | £18.85 M | -61.48% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | £8.82 B | 17,924.11% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | N/A | N/A | 🇺🇸 USA |